Tag Archives: Dr. Harald Hasselmann

Eckert & Ziegler Hosts Successful 3rd Boston Radionuclide Theranostics Forum to Shape the Future of Precision Oncology

(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release

Eckert & Ziegler Honored with the “Best Managed Companies Award” for Exceptional Leadership and Innovation

(IN BRIEF) Eckert & Ziegler SE has been awarded the “Best Managed Companies Award” for the second time, a prestigious recognition celebrating excellence in strategy, innovation, culture, and governance. This accolade underscores the company’s continued leadership in supplying isotopes for … Read the full press release

Empowering Radiopharmaceutical Innovation: A Global Supply Pact Between Eckert & Ziegler and AtomVie

(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release

Eckert & Ziegler and Ariceum Therapeutics Forge Global Supply Agreement for Critical Medical Radionuclides

(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release

Eckert & Ziegler’s Theralugand® Gains EU Approval for Advanced Cancer Therapies

(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release

Eckert & Ziegler’s GalliaPharm® Generator Powers Groundbreaking Cancer Diagnostic Trial in Japan

(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release